ESTRO 2025 - Abstract Book

S2035

Clinical - Urology

ESTRO 2025

Conclusion: This real-world study from a single center shows the efficacy of ADT combined with NTH in achieving deep PSA responses and improving survival in mHSPC patients. Deep PSA nadir and low-volume disease were identified as a key biomarker for better outcomes. The manageable toxicity profile of NHT supports their application into our clinical practice.

Keywords: Metastatic, Hormone-sensitive, Prostate cancer

References: Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, et al. Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study. Urol Oncol. (2023) 41:252.e19 – 252.e27 Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. (2022) 129:423 – 33 Hoeh B, Garcia CC, Wenzel M, Tian Z, Tilki D, Steuber T, et al. Triplet or doublet therapy in metastatic hormone sensitive prostate cancer: updated network meta-analysis stratified by disease volume. Eur Urol Focus. (2023) 9:838 – 42

3134

Digital Poster Radical Radiotherapy OVER 80 years old (ROVER-80): a Polish multi-centre study

Aleksandra Napieralska 1,2 , Wojciech Kamzol 3 , Katarzyna Serwańska 4 , Martyna Krawczyk 4 , Beata Ciborowska Zielińska 5 , Michał Falco 5 , Anna Romanowska 6 , Dagmara Buczek 7 , Anna Misiorowska 1 , Donata Graupner 8 , Joanna Socha 9,10 , Emilia Krzywonos 2 , Adrianna Chudyba 2 , Rafał Stando 11 , Grzegorz Chmielewski 11,12 , Katarzyna Konat Bąska 13 , Magdalena Socha-Stojek 14 , Joanna Niedziałek 14 , Alicja Dobrakowska 14 , Maciej Głowacki 15 , Monika Sadlik Krępa 15 , Michał Dec 16 , Michał Posiewnik 16 , Adam Zięba 17 , Nina Jędrzejczak 17 1 Radiotherapy Department, Maria Skłodowska -Curie National Research Institute of Oncology, Gliwice, Poland. 2 Radiotherapy Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow, Poland. 3 Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4 Radiotherapy Department, Amethyst Radiotherapy Centre, Rydygier Hospital, Cracow, Poland. 5 Radiotherapy Department, West Pomeranian Oncology Centre, Szczecin, Poland. 6 Department of Oncology and Radiotherapy, University Clinical